News

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...
The American Journal of Managed Care44m
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure ...
Consilium1d
The pharma package: new EU rules on medicines
The purpose of the pharma package is to revise the current rules on medicines to make them more accessible to patients while ...
CURE2h
Iopofosine-131 Earns FDA Breakthrough for Waldenstrom Macroglobulinemia
Iopofosine-131 received FDA breakthrough status for relapsed or refractory Waldenstrom macroglobulinemia, showing strong ...
Medical Dialogues9h
Roche Evrysdi tablet gets European Commission approval for Spinal Muscular Atrophy
Basel: Roche has announced that the European Commission (EC) has approved a label extension for Evrysdi (risdiplam) to ...
Medscape13d
Blenrep Gets European Nod to Treat Multiple Myeloma
Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...
Pharmabiz14h
European Commission approves Roche’s Evrysdi tablet to treat spinal muscular atrophy
European Commission approves Roche’s Evrysdi tablet to treat spinal muscular atrophy: Basel Thursday, June 5, 2025, 09:00 Hrs [IST] Roche announced that the European Commission ...